Abstract
Protein tyrosine phosphatases (PTPs) are crucial regulators for numerous biological processes in nature. The dysfunction and overexpression of many PTP members have been demonstrated to cause fatal human diseases such as cancers, diabetes, obesity, neurodegenerative diseases and autoimmune disorders. In the past decade, considerable efforts have been devoted to the production of PTPs inhibitors by both academia and the pharmaceutical industry. However, there are only limited drug candidates in clinical trials and no commercial drugs have been approved, implying that further efficient discovery of novel chemical entities competent for inhibition of the specific PTP target in vivo remains yet a challenge. In light of the click-chemistry paradigm which advocates the utilization of concise and selective carbon-heteroatom ligation reactions for the modular construction of useful compound libraries, the Cu(I)-catalyzed azidealkyne 1,3-dipolar cycloaddition reaction (CuAAC) has fueled enormous energy into the modern drug discovery. Recently, this ingenious chemical ligation tool has also revealed efficacious and expeditious in establishing large combinatorial libraries for the acquisition of novel PTPs inhibitors with promising pharmacological profiles. We thus offer here a comprehensive review highlighting the development of PTPs inhibitors accelerated by the CuAAC click chemistry.
Keywords: Protein tyrosine phosphatase, click chemistry, in situ screening, drug discovery, CuAAC, tyrosine phosphorylation, dephosphorylation, carbohydrate, amino acid, salicylic acid, isoxazole acid, ketocarboxylic acid, competitive inhibitor, bidentate
Current Medicinal Chemistry
Title:CuAAC Click Chemistry Accelerates the Discovery of Novel Chemical Scaffolds as Promising Protein Tyrosine Phosphatases Inhibitors
Volume: 19 Issue: 15
Author(s): X. -P. He, J. Xie, Y. Tang, J. Li, G. -R. Chen
Affiliation:
Keywords: Protein tyrosine phosphatase, click chemistry, in situ screening, drug discovery, CuAAC, tyrosine phosphorylation, dephosphorylation, carbohydrate, amino acid, salicylic acid, isoxazole acid, ketocarboxylic acid, competitive inhibitor, bidentate
Abstract: Protein tyrosine phosphatases (PTPs) are crucial regulators for numerous biological processes in nature. The dysfunction and overexpression of many PTP members have been demonstrated to cause fatal human diseases such as cancers, diabetes, obesity, neurodegenerative diseases and autoimmune disorders. In the past decade, considerable efforts have been devoted to the production of PTPs inhibitors by both academia and the pharmaceutical industry. However, there are only limited drug candidates in clinical trials and no commercial drugs have been approved, implying that further efficient discovery of novel chemical entities competent for inhibition of the specific PTP target in vivo remains yet a challenge. In light of the click-chemistry paradigm which advocates the utilization of concise and selective carbon-heteroatom ligation reactions for the modular construction of useful compound libraries, the Cu(I)-catalyzed azidealkyne 1,3-dipolar cycloaddition reaction (CuAAC) has fueled enormous energy into the modern drug discovery. Recently, this ingenious chemical ligation tool has also revealed efficacious and expeditious in establishing large combinatorial libraries for the acquisition of novel PTPs inhibitors with promising pharmacological profiles. We thus offer here a comprehensive review highlighting the development of PTPs inhibitors accelerated by the CuAAC click chemistry.
Export Options
About this article
Cite this article as:
X. -P. He, J. Xie, Y. Tang, J. Li, G. -R. Chen , CuAAC Click Chemistry Accelerates the Discovery of Novel Chemical Scaffolds as Promising Protein Tyrosine Phosphatases Inhibitors, Current Medicinal Chemistry 2012; 19 (15) . https://dx.doi.org/10.2174/092986712800269245
DOI https://dx.doi.org/10.2174/092986712800269245 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fecal DNA Genotyping: A Non-invasive Approach to Characterize Mouse Models for Nutrigenomics Cancer Chemoprevention Studies
Current Pharmacogenomics and Personalized Medicine Synthesis of Fluorine-18-Labelled Choline (<sup>18</sup>F-Fluorocholine): Towards an Early and Accurate Management of Prostate Cancer in Malaysia
Current Medical Imaging Geldanamycin, Radicicol, and Chimeric Inhibitors of the Hsp90 Nterminal ATP Binding Site
Current Topics in Medicinal Chemistry Dendrimers and the Development of New Complex Nanomaterials for Biomedical Applications
Current Medicinal Chemistry Pharmaceutical Nanotechnology United States Patent Watch (January – March 2016)
Pharmaceutical Nanotechnology PAI-1 - A Potential Therapeutic Target in Cancer
Current Drug Targets Proteomic Validation of Protease Drug Targets: Pharmacoproteomics of Matrix Metalloproteinase Inhibitor Drugs Using Isotope-Coded Affinity Tag Labelling and Tandem Mass Spectrometry
Current Pharmaceutical Design Tamoxifen Resistance and Epigenetic Modifications in Breast Cancer Cell Lines
Current Medicinal Chemistry Development of Prolactin Receptor Antagonists: Same Goal, Different Ways
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers
Current Cancer Drug Targets An Overview on Pyranocoumarins: Synthesis and Biological Activities
Current Organic Chemistry Bevacizumab for Malignant Brain Gliomas. Which is the Current Evidence?
Recent Patents on Inflammation & Allergy Drug Discovery Herbal Interactions with Anticancer Drugs: Mechanistic and Clinical Considerations
Current Medicinal Chemistry Preclinical and Clinical Efficacy of the Bisphosphonate Ibandronate in Cancer Treatment
Current Clinical Pharmacology Nanostructured Systems for the Organelle-specific Delivery of Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Neurodegeneration in the Brain Tumor Microenvironment: Glutamate in the Limelight
Current Neuropharmacology Kinase Inhibitors Targeting Anti-angiogenesis as Anti-cancer Therapies
Current Angiogenesis (Discontinued) Endomorphin Derivatives with Improved Pharmacological Properties
Current Medicinal Chemistry Cytoprotection and Immunomodulation in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Preparation and <i>In-vitro</i> Evaluation of Levan Micelles: A Polyfructan Based Nano-carrier for Breast Cancer Targeted Delivery
Drug Delivery Letters